Brown, Lisle/Cummings, Inc. Viking Therapeutics, Inc. Transaction History
Brown, Lisle/Cummings, Inc.
- $390 Billion
- Q3 2025
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 400 shares of VKTX stock, worth $15,168. This represents 0.0% of its overall portfolio holdings.
Number of Shares
400
Previous 400
-0.0%
Holding current value
$15,168
Previous $10.6 Million
0.83%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
452Shares Held
67.9MCall Options Held
7.72MPut Options Held
3.25M-
Vanguard Group Inc Valley Forge, PA10.2MShares$385 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$229 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$143 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.25MShares$123 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$119 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.91B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...